Brokerage_OptimizedHRT

The chart shows the growth of an initial investment of $10,000 in Brokerage_OptimizedHRT, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Nov 8, 2024, Brokerage_OptimizedHRT's average daily return is +0.10%, while the average monthly return is +1.92%. At this rate, your investment would double in approximately 3.0 years.

Historically, 61% of months were positive and 39% were negative. The best month was Jun 2025 with a return of +10.6%, while the worst month was Mar 2025 at -8.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.

On a daily basis, Brokerage_OptimizedHRT closed higher 56% of trading days. The best single day was Apr 9, 2025 with a return of +12.3%, while the worst single day was Apr 4, 2025 at -6.9%.

Brokerage_OptimizedHRT has an annualized alpha of 15.36%, beta of 1.41, and R² of 0.85 versus S&P 500 Index. Calculated based on daily prices since November 08, 2024.

• This portfolio captured 216.74% of S&P 500 Index gains and 108.87% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• This portfolio generated an annualized alpha of 15.36% versus S&P 500 Index — delivering returns beyond what market exposure alone would predict.

Brokerage_OptimizedHRT has an expense ratio of 0.33%, placing it in the medium range. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Brokerage_OptimizedHRT ranks 58 for risk / return — on par with similar portfolios. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Brokerage_OptimizedHRT Sharpe ratios as of Apr 3, 2026 (values are recalculated daily):

• 1-Year: 1.42
• All Time: 0.96

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 0.98 to 1.66, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Brokerage_OptimizedHRT compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Brokerage_OptimizedHRT provided a 0.21% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Brokerage_OptimizedHRT. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Brokerage_OptimizedHRT was 26.46%, occurring on Apr 8, 2025. Recovery took 41 trading sessions.

The current Brokerage_OptimizedHRT drawdown is 13.52%.

The chart below shows the rolling one-month volatility.